Dual-Action vs. Single-Hormone Weight-Loss Medications
By Charles Kamen, MD, board-certified neurologist
In clinical trials, tirzepatide has produced greater average weight loss than semaglutide: about 21% of body weight at 72 weeks in SURMOUNT-1, versus roughly 15% at 68 weeks for semaglutide in the STEP program. Both are once-weekly injectable incretin therapies, but they act on different receptors. [4]
Board-certified neurologist Dr. Charles Kamen, MD (Albert Einstein College of Medicine), of LiveNow Longevity in Las Vegas, helps patients compare these options as part of a broader metabolic plan. Individual results vary depending on metabolic factors, adherence, and clinical supervision.
How Do Semaglutide and Tirzepatide Work Differently?
Semaglutide activates one receptor; tirzepatide activates two. Semaglutide is a selective GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate appetite and insulin secretion. Tirzepatide is a dual agonist that stimulates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor — a combination linked to greater weight loss in clinical trials. [1][2]
Both medications act largely through the brain's appetite centers: GLP-1 receptors in the hypothalamus and brainstem reduce hunger and slow gastric emptying. As a neurologist, Dr. Kamen pays close attention to how these central mechanisms shape appetite, satiety, and energy. [3]
How Much Weight Loss Do Clinical Trials Show?
In clinical trials, tirzepatide reduced body weight by approximately 21% at 72 weeks (SURMOUNT-1), while semaglutide produced approximately 15% at 68 weeks in the STEP program. A later head-to-head trial, SURMOUNT-5, compared the two agents directly. Available evidence suggests tirzepatide may produce greater average weight loss, though individual responses vary widely. [4][8]
Trial averages are not promises. Real-world results depend on dose tolerance, adherence, diet, and activity, which is why Dr. Kamen frames these numbers as ranges rather than targets.
What Happens to Muscle and Visceral Fat?
Weight loss on any incretin therapy includes both fat and lean mass, so protecting muscle is a clinical priority rather than an afterthought. These medications also reduce visceral and ectopic fat — the metabolically active fat around the organs that most affects long-term metabolic and cardiovascular health.
Dr. Kamen pairs therapy with adequate protein, resistance training, and monitoring so that the weight lost is preferentially fat, not the muscle that protects metabolism, strength, and healthspan. The goal is better body composition and insulin sensitivity — not just a lower number on the scale. [7]
How Are Semaglutide and Tirzepatide Dosed?
Both semaglutide and tirzepatide are once-weekly subcutaneous injections, started at a low dose and escalated gradually to limit side effects. Both require refrigeration and proper storage, and both depend on consistent weekly dosing to maintain their appetite and metabolic effects. [5]
Dr. Kamen determines the appropriate starting dose and escalation schedule during your initial consultation at the Las Vegas clinic, adjusting based on your tolerance and response.
What Are the Side Effects of Semaglutide and Tirzepatide?
Both medications share a similar, mostly gastrointestinal side-effect profile. The most common effects are nausea, diarrhea, and constipation, which tend to be strongest during dose escalation and ease over time. Some evidence suggests tirzepatide may cause slightly fewer of certain gastrointestinal effects despite its dual action, though tolerance is highly individual. [6]
- Nausea — the most common effect, usually strongest when the dose is increased.
- Diarrhea and constipation — frequent gastrointestinal effects that often settle with time and slow titration.
- Reduced appetite and early fullness — expected effects that also drive the weight loss.
Who Should Consider Each Medication?
The right choice depends on your metabolic profile, treatment history, and goals. Semaglutide may suit patients with type 2 diabetes and obesity who prefer a well-established medication, while tirzepatide may benefit those who have not reached their goals on GLP-1 therapy alone or whose metabolic profile responds to dual receptor agonism. [7]
Dr. Kamen evaluates each patient individually — labs, insulin sensitivity, and history — to determine the most clinically appropriate option, rather than defaulting to whichever medication is most talked about.
Key Takeaways
- Tirzepatide reduced body weight by about 21% at 72 weeks in SURMOUNT-1; semaglutide about 15% at 68 weeks in the STEP program.
- Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist.
- Both are once-weekly subcutaneous injections that require gradual dose escalation and refrigeration.
- Side effects are mainly gastrointestinal — nausea, diarrhea, and constipation — and often ease with titration.
- Weight loss includes lean mass, so preserving muscle and targeting visceral fat is a clinical priority.
- Dr. Kamen selects the medication individually based on metabolic labs, history, and goals in Las Vegas.
Common Questions
Is tirzepatide better than semaglutide for weight loss?
In clinical trials, tirzepatide produced greater average weight loss — about 21% at 72 weeks versus roughly 15% for semaglutide — but the better option depends on the individual. Response varies with metabolic profile, tolerance, and adherence, so Dr. Kamen evaluates each patient to choose the most clinically appropriate medication.
Will I lose muscle on semaglutide or tirzepatide?
Some lean mass is lost alongside fat with any rapid weight loss, including on these medications. To protect muscle, Dr. Kamen pairs therapy with adequate protein, resistance training, and monitoring, so the weight you lose is preferentially fat — including the visceral fat that most affects metabolic and cardiovascular health.
Can I switch from semaglutide to tirzepatide?
Yes, when clinically appropriate. If you have not reached your goals on semaglutide or tolerate it poorly, Dr. Kamen can review your progress, labs, and history to determine whether switching to the dual receptor action of tirzepatide is medically appropriate for your situation.
What are the most common side effects?
Both medications share a mostly gastrointestinal profile — nausea, diarrhea, and constipation — usually strongest during dose escalation and easing over time. Some evidence suggests tirzepatide may cause slightly fewer of certain gastrointestinal effects, but tolerance is individual. Slow titration and dietary changes help most patients.
Do I need blood work before starting?
Yes. Before initiating either medication, Dr. Kamen orders labs to evaluate metabolic function, insulin sensitivity, and related factors. This baseline confirms the therapy is appropriate, guides dosing, and lets him track improvements in blood sugar and body composition over the course of treatment.
What happens to my weight if I stop the medication?
Weight regain can occur after stopping, as with any weight-management therapy, because the appetite and metabolic effects fade once the medication is discontinued. Sustaining results requires ongoing lifestyle support — protein, resistance training, and follow-up — which Dr. Kamen builds into the plan from the start.
Both semaglutide and tirzepatide are significant advances in medical weight management, and the right choice depends on your metabolic profile, clinical history, and goals — not on which medication gets the most attention. Schedule a consultation with Dr. Kamen at LiveNow Longevity to determine which option may be right for you.
References
- Coskun T, Sloop KW, Loghin C, et al. Mol Metab. 2018;18:3-14. (LY3298176/tirzepatide, a novel dual GIP and GLP-1 receptor agonist).
- Drucker DJ. Cell Metab. 2024;39(4):523-538.
- Holst JJ, et al. Lancet. 2021;398(10295):143-155.
- Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. (SURMOUNT-1).
- FDA. Zepbound Prescribing Information. 2024.
- Frías JP, et al. N Engl J Med. 2021;385(6):503-515. (SURPASS-2, tirzepatide vs semaglutide in T2D).
- France NL, Syed YY. Drugs. 2024;84(2):227-238. (Tirzepatide: a review, including patient selection and clinical use).
- Aronne LJ, et al. N Engl J Med. 2025;393:26-36. (SURMOUNT-5 head-to-head).
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.